After 21–28 days, CD3+CD56+ cells, derived from CD3+CD56− cells, acquire cytotoxicity against various tumor cell targets, including AML, chronic myeloid leukemia, and B-cell and T-cell lymphoma. This evidence concerns the gene NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive.